161 related articles for article (PubMed ID: 29520101)
1. Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole.
Minato Y; Dawadi S; Kordus SL; Sivanandam A; Aldrich CC; Baughn AD
Nat Commun; 2018 Mar; 9(1):1003. PubMed ID: 29520101
[TBL] [Abstract][Full Text] [Related]
2. Deletion of
Li K; Li T; Yang SS; Wang XD; Gao LX; Wang RQ; Gu J; Zhang XE; Deng JY
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223385
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of in vitro sensitivity testing methods of detecting sulphamethoxazole trimethoprim synergy. Correlation with mouse protection assay.
Rawal BD; Cottis L
Arzneimittelforschung; 1980; 30(7):1049-51. PubMed ID: 6998489
[TBL] [Abstract][Full Text] [Related]
4. A correlation with type of sulfonamide resistance gene in Escherichia coli and synergy between trimethoprim and sulfamethoxazole.
Valentine CR; Hawk JM; Christian MM; Youmans RW
J Basic Microbiol; 1992; 32(3):201-7. PubMed ID: 1512711
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Nocardia cyriacigeorgica and Nocardia nova Evolve To Resist Trimethoprim-Sulfamethoxazole by both Expected and Unexpected Pathways.
Mehta H; Weng J; Prater A; Elworth RAL; Han X; Shamoo Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686152
[No Abstract] [Full Text] [Related]
6. Lack of activity of sulfamethoxazole and trimethoprim against anaerobic bacteria.
Rosenblatt JE; Stewart PR
Antimicrob Agents Chemother; 1974 Jul; 6(1):93-7. PubMed ID: 15828176
[TBL] [Abstract][Full Text] [Related]
7. Dissemination of Trimethoprim-Sulfamethoxazole Drug Resistance Genes Associated with Class 1 and Class 2 Integrons Among Gram-Negative Bacteria from HIV Patients in South India.
Ramesh Kumar MR; Arunagirinathan N; Srivani S; Dhanasezhian A; Vijaykanth N; Manikandan N; Balakrishnan S; Vignesh R; Balakrishnan P; Solomon S; Solomon SS
Microb Drug Resist; 2017 Jul; 23(5):602-608. PubMed ID: 27854149
[TBL] [Abstract][Full Text] [Related]
8. Influence of ionizing radiation on the antimicrobial activity of the antibiotics sulfamethoxazole and trimethoprim.
Sági G; Szabacsi K; Szabó L; Homlok R; Kovács K; Mohácsi-Farkas C; Pillai SD; Takács E; Wojnárovits L
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2018 Jul; 53(8):687-693. PubMed ID: 29485359
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country.
Gangcuangco LM; Alejandria M; Henson KE; Alfaraz L; Ata RM; Lopez M; Saniel M
Int J Infect Dis; 2015 May; 34():55-60. PubMed ID: 25748571
[TBL] [Abstract][Full Text] [Related]
10. The use of trimethoprim and sulfamethoxazole (TMP-SMX) in dermatology.
Michałek K; Lechowicz M; Pastuszczak M; Wojas-Pelc A
Folia Med Cracov; 2015; 55(1):35-41. PubMed ID: 26774630
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis and trimethoprim-sulfamethoxazole.
Forgacs P; Wengenack NL; Hall L; Zimmerman SK; Silverman ML; Roberts GD
Antimicrob Agents Chemother; 2009 Nov; 53(11):4789-93. PubMed ID: 19564358
[TBL] [Abstract][Full Text] [Related]
12. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus.
Close SJ; McBurney CR; Garvin CG; Chen DC; Martin SJ
Pharmacotherapy; 2002 Aug; 22(8):983-9. PubMed ID: 12173801
[TBL] [Abstract][Full Text] [Related]
13. New therapy from old drugs: synergistic bactericidal activity of sulfadiazine with colistin against colistin-resistant bacteria, including plasmid-mediated colistin-resistant mcr-1 isolates.
Okdah L; Le Page S; Olaitan AO; Dubourg G; Hadjadj L; Rolain JM
Int J Antimicrob Agents; 2018 May; 51(5):775-783. PubMed ID: 29421171
[TBL] [Abstract][Full Text] [Related]
14. Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.
Greenwood D; O'Grady F
J Clin Pathol; 1976 Feb; 29(2):162-6. PubMed ID: 777036
[TBL] [Abstract][Full Text] [Related]
15. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.
Falagas ME; Vardakas KZ; Roussos NS
Int J Antimicrob Agents; 2015 Sep; 46(3):231-41. PubMed ID: 26070662
[TBL] [Abstract][Full Text] [Related]
16. Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.
Rosenblatt JE; Stewart PR
Antimicrob Agents Chemother; 1974 Jul; 6(1):84-92. PubMed ID: 15828175
[TBL] [Abstract][Full Text] [Related]
17. Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.
Muñoz JL; García MI; Muñoz S; Leal S; Fajardo M; Garćia-Rodríguez JA
Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):879-82. PubMed ID: 8997563
[TBL] [Abstract][Full Text] [Related]
18. Decomposition of sulfamethoxazole and trimethoprim by continuous UVA/LED/TiO
Cai Q; Hu J
J Hazard Mater; 2017 Feb; 323(Pt A):527-536. PubMed ID: 27324695
[TBL] [Abstract][Full Text] [Related]
19. Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men.
Witt JM; Koo JM; Danielson BD
Ann Pharmacother; 1996 Apr; 30(4):347-50. PubMed ID: 8729886
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial synergism in the therapy of experimental cerebral nocardiosis.
Gombert ME; duBouchet L; Aulicino TM; Berkowitz LB
J Antimicrob Chemother; 1989 Jul; 24(1):39-43. PubMed ID: 2674100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
